1887

oa SA Pharmaceutical Journal - New drug focus

 

Abstract

Extracted from text ... SA Pharmaceutical Journal - April 2006 40 DRUG INFO Protos(r) - The first of a new class for osteoporosis: dual action bone agent Approved indication Protos(r) contains strontium ranelate and is indicated for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and peripheral fractures, including the hip. Mode of action Strontium ranelate has a unique pharmacological profile characterised by an inhibition of bone resorption and a simultaneous stimulation of bone formation. It targets the bone remodelling process by stimulating osteoblast-mediated bone formation and by inhibiting osteoclast-mediated bone resorption. The dual mode of action of strontium ranelate may ..

Loading

Article metrics loading...

/content/mp_sapj/73/3/EJC81471
2006-04-01
2016-12-07
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error